SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is seeing significant upward momentum as investors speculate on a major buyout and the upcoming Phase 3 REGAL trial data, with community discourse heavily focused on a potential short squeeze fueled by high short interest and limited share availability. Long-term shareholders are actively sharing deep-dive research and maintaining high conviction in the stock's clinical potential, while many are cautioning others against panic selling or setting stop-loss orders in the face of ongoing volatility.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as investors weigh potential catalysts like the upcoming July Ducati showcase against volatility driven by heavy short interest and skepticism over the company's timeline to commercialization. Community discourse remains deeply divided between those betting on the long-term potential of its solid-state battery tech and others frustrated by the stock's lack of consistent upward momentum.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the market braces for a pivotal late-July advisory committee meeting to discuss deramiocel, with investors debating the potential for a broad label approval despite recent stock volatility. The community remains focused on the company's long-term clinical data, ongoing legal proceedings regarding distribution rights, and expectations for a major institutional shift in regulatory sentiment.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is currently trending as investors debate whether the stock represents a deep-value opportunity at decade-low prices or a structural value trap ahead of upcoming earnings. Community sentiment is deeply polarized, with bulls pointing to the strength of the brand and recent executive shifts to justify an accumulation strategy, while bears remain focused on declining market share, competitive headwinds, and persistent concerns over growth in China.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is trending as shares dropped following reports of raids on its Taiwan offices by local authorities, which investors fear marks an expansion of a widening probe into alleged unauthorized AI chip exports to China. While community bulls contend this is old, recycled news meant to induce panic selling and dismiss the company as an innocent party cooperating with investigations, bears argue the regulatory overhang and lack of management transparency make the stock increasingly uninvestable.

AeroVironment, Inc. is a defense technology company delivering integrated capabilities across air, land, sea, space, and cyber. The company develops and deploys autonomous systems, loitering munitions, counter-UAS technologies, space-based platforms, directed energy systems, and cyber and electronic warfare capabilities-built to meet the mission needs of today’s warfighter and tomorrow’s conflicts. At the core of these technologies lies AV_Halo, a modular, mission-ready suite of AI-powered software tools that empowers warfighters and enables full-battlefield dominance: detect, decide, deliver. With a national manufacturing footprint and a deep innovation pipeline, AV delivers proven systems and future-defining capabilities at speed, scale, and operational relevance. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is trending as investors react to strong earnings and significant growth in its backlog, fueling community debate over the company's long-term profitability versus its top-line success. The stock is seeing heightened activity as market participants weigh recent contract news and broader defense sector dynamics against concerns over forward guidance.

Applied Materials, Inc. engages in provision of materials engineering solutions used to produce semiconductors. The firm also focuses on design, development, production, and servicing of the critical wafer fabrication tools used for customers to manufacture semiconductors. It operates through the following segments: Semiconductor Systems and Applied Global Services (AGS). The Semiconductor Systems segment includes designing, development, manufacturing and sale of equipment used to fabricate semiconductor chips referred to as integrated circuits. The AGS segment engages in provision of services, spares, and factory automation software to customer fabrication plants globally. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials is trending due to a wave of analyst price-target hikes following strong quarterly earnings and an optimistic outlook on AI-driven semiconductor infrastructure demand. The community is actively debating the stock's parabolic momentum, the impact of institutional profit-taking, and its role as a key equipment provider in the ongoing semiconductor supercycle.

Jack in the Box, Inc. engages in the provision of developing, operating, and franchising a chain of quick-service and fast-casual restaurants. It operates through the Jack in the Box and Del Taco segments. The Jack in the Box segment offers a selection of distinctive products including classic burgers and other product lines such as Buttery Jack Burgers. The company was founded by Robert Oscar Peterson in 1951 and is headquartered in San Diego, CA.

Jack In The Box, Inc.

Jack in the Box is trending as investors debate its potential as a short-squeeze candidate, driven by reports of high short interest and a relatively low share float. While some traders are betting on a turnaround fueled by debt restructuring and operational pivots, others remain skeptical due to the company's significant debt load and ongoing competition in the fast-food sector.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

iShares Silver Trust is experiencing significant volatility and a sharp sell-off, driven by macroeconomic factors like interest rate concerns, a strengthening dollar, and a broader liquidity reset across commodities. The community is deeply polarized, with bulls actively accumulating during the dip citing long-term industrial demand from AI and energy sectors, while bears point to technical breakdowns and the reversal of geopolitical risk premiums.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Churchill Capital Corp XI - Ordinary Shares - Class A

Churchill Capital Corp XI is gaining significant momentum as investors digest news of its merger with Agility Robotics, which many see as the first pure-play opportunity in the humanoid robotics sector. Community discussion is heavily focused on the stock's low float and the backing of major tech industry players, with many retail participants actively debating the potential for long-term growth and comparing the ticker's trajectory to previous SPAC success stories.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Makes Nuvectis Pharma (NVCT) a New Buy Stock

Nuvectis Pharma (NVCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Nuvectis Pharma Jumps 20% To 52-Week High  Here's Why NVCT Stock Is Trending

NVCT stock jumped after Nuvectis expanded its pipeline through a licensing deal with Haisco.read more...

Wall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a Bet

The mean of analysts' price targets for Nuvectis Pharma (NVCT) points to a 57% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Nuvectis Pharma (NVCT) Could Rally 62.5%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 62.5% in Nuvectis Pharma (NVCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Nuvectis Pharma (NASDAQ:NVCT) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Nuvectis Pharma (NASDAQ:NVCT - Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.04...

Nuvectis Pharma (NVCT) Projected to Post Earnings on Tuesday

Nuvectis Pharma (NASDAQ:NVCT) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-5-nuvectis-pharma-inc-stock...

Nuvectis Pharma, Inc. $NVCT Shares Acquired by Iridian Asset Management LLC CT

Iridian Asset Management LLC CT increased its holdings in Nuvectis Pharma, Inc. (NASDAQ:NVCT - Free Report) by 44.5% during the fourth quarter, according to its most recent filing with the Securities...

Nuvectis Pharma (NASDAQ:NVCT) Trading Down 1.7%  - Here's What Happened

Nuvectis Pharma (NASDAQ:NVCT) Shares Down 1.7% - What's Next...

Nuvectis Pharma (NASDAQ:NVCT) Shares Up 6.3% - Still a Buy?

Nuvectis Pharma (NASDAQ:NVCT) Shares Up 6.3% - Still a Buy...

Nuvectis Pharma (NVCT) to Release Quarterly Earnings on Tuesday

Nuvectis Pharma (NASDAQ:NVCT) will be releasing its Q4 2025 earnings before the market opens on Tuesday, February 24. (View Earnings Report at...

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. Its product pipeline includes NXP800 and NXP900. The company was founded by Ronald E. Bentsur, Enrique Poradosu, and Shay Shemesh on July 27, 2020 and is headquartered in Fort Lee, NJ.

Nuvectis Pharma Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.26	--	--	N/A
Q1 '26	-$0.31	-$0.26	17.20%	BEAT
Q4 '25	-$0.32	-$0.31	1.90%	BEAT
Q3 '25	-$0.25	-$0.44	-76.00%	MISSED
Q2 '25	-$0.25	-$0.30	-19.21%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

NVCTNuvectis Pharma Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest NVCT News